修订后的HLA-DP TCE-Core允许性模型更好地定义了随机移植后的复发风险和生存率
Scott R Solomon1, Michael T Aubrey2, Lizamarie Bachier-Rodriguez1
1The Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia.
Transplantation and cellular therapy
|April 1, 2024
概括
对HLA-DPB1不匹配的修订后TCE-Core模型改善了用移植后环胺 (PTCy) 进行平分异性供体移植 (HIDT) 的生存预测. 这种模型更好地识别非容许性不匹配,减少复发风险,而不会增加移植对宿主疾病或非复发死亡率.
科学领域:
- 免疫遗传学 免疫遗传学
- 造血干细胞移植 造血干细胞移植
- 在 HLA 匹配上.
背景情况:
- 使用TCE-3模型的HLA-DPB1非容许性不匹配 (NPMM) 与与移植后环酸胺 (PTCy) 进行的平分异性供体移植 (HIDT) 中更好的结果有关.
- 一个修订后的模型,TCE-Core,将TCE-3"第三组"等位基因的分类改进为"核心" (C) 和"非核心" (NC),将一些以前允许的不匹配重新分类为C-NPMM.
研究的目的:
- 评估HLA-DPB1 C-NPMM对HIDT结果的影响,根据TCE-Core算法定义.
- 评估不匹配的方向向量 (移植对宿主对宿主对移植) 对移植结果的影响.
- 为了比较TCE-Core模型与传统的TCE-3算法预测生存的歧视力.
主要方法:
- 在2005年至2021年间接种的242名连续HIDT接受者患有急性白血病或骨髓质疏松综合征的分析.
- 使用TCE-Core算法识别C-NPMMs的136个TCE-3允许不匹配的重新分类.
- 允许和不允许组之间的整体存活率 (OS) 和无病存活率 (DFS) 的比较,考虑到不匹配的方向性.
主要成果:
- 与TCE-3相比,TCE-Core模型发现了较高比例的非允许移植 (38%对23%),并显示了较大的生存益处.
- TCE-Core定义的非宽容性HLA-DP不匹配与更高的5年生存率 (66%vs. 47%) 和DFS (60%vs. 43%) 相关.
- 多变量分析证实,非允许的TCE-Core不匹配显著改善了OS和DFS,主要是通过降低复发风险 (HR, .63;P = .049),而不会对GVHD或NRM产生不利影响.
结论:
- TCE-Core算法提供了更准确的HLA-DP不匹配状态评估,显著预测了基于PTCy的HIDT的改善生存率.
- 与TCE-Core定义的非容许性不匹配相关的复发风险的降低可以改善患者的治疗结果,而不会增加死亡率或GVHD.
- TCE-Core作为一个优秀的捐赠者选择工具,更好地区分HIDT结果,并可能扩大捐赠者池.
相关概念视频
Tissue Transplantation
366
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
366
Cell-mediated Immune Responses
68.2K
Overview
68.2K
Bone Marrow Sampling and Transplants
328
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
328


